S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?

AbbVie (ABBV) Stock Price, News & Analysis

$181.97
+1.62 (+0.90%)
(As of 03/28/2024 ET)
Today's Range
$180.30
$182.29
50-Day Range
$163.29
$181.18
52-Week Range
$130.96
$182.89
Volume
5.42 million shs
Average Volume
5.70 million shs
Market Capitalization
$322.21 billion
P/E Ratio
66.66
Dividend Yield
3.41%
Price Target
$177.43

AbbVie MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.71 Rating Score
Upside/​Downside
2.5% Downside
$177.43 Price Target
Short Interest
Healthy
0.83% of Float Sold Short
Dividend Strength
Strong
Based on Four Factors
Sustainability
-2.34
Upright™ Environmental Score
News Sentiment
0.57mentions of AbbVie in the last 14 days
Based on 49 Articles This Week
Insider Trading
Selling Shares
$67.78 M Sold Last Quarter
Proj. Earnings Growth
9.42%
From $11.15 to $12.20 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.77 out of 5 stars

Medical Sector

61st out of 938 stocks

Pharmaceutical Preparations Industry

25th out of 425 stocks

ABBV stock logo

About AbbVie Stock (NYSE:ABBV)

AbbVie Inc. is a US-based biopharma company with global operations. The company originated as the bio-pharma segment of Abbott Laboratories and was spun off in late 2012. The company officially IPOd on January 2, 2013; contrary to criticisms, the move was solely to protect the parent company from expiring patents. Post-spin, AbbVie emerged as a research-based biopharma that has more than doubled in size. AbbVie, like its parent Abbot Laboratories, is a well-established dividend growth stock.

Over the years, AbbView Inc. has made numerous acquisitions. Among the more notable are ImmuVen, Pharamcyclics and Allergan plc. Allergan plc was an Ireland-based pharmaceutical company focused on health-oriented aesthetic products and is the owner of Botox. Botox accounts for the bulk of the company’s Aesthetics portfolio revenue and about 4% of the net as of 2022. The total revenue in 2021 was $56.20 billion with a 31% operating margin.

Today, AbbVie operates as a diversified multi-national pharmaceutical company with a patient-centric approach to research. It is in business to discover, develop, manufacture and market pharmaceuticals globally but in a way that best serves the needs of patients and the global community.

The company’s original winner, Humira, is still the number one revenue source but the portfolio has been greatly expanded. Other profitable therapies include but are not limited to SKYRIZI for psoriasis, RINVOQ for rheumatoid arthritis and IMBRUVICA and VENCLEXTA for chronic leukemia conditions.

The company is focused on research and has a number of collaborations and partnerships to that end. Among the many avenues of research and innovation are the advancement of precision medicine or pMedicine. PMeds are designed not only to target the specific causes of diseases, often at the genetic level, but the patients that are most likely to benefit from them. Assuming there are 2 highly effective drugs for 1 disease, PMedicine seeks to identify which patients respond better to each.

As of 2022, AbbVie employed more than 50,000 people globally with 21,000 in STEM-related positions. To date, the company had invested more than $50 billion into research through more than 250 partnerships. Partnerships are with universities, medical facilities, research organizations and other pharmaceutical companies. The company’s operations span 20 countries, treating more than 60 million people and 40 conditions annually.

AbbVie has 5 focus areas for its research and products. These are Immunology, Oncology, Neurology, Virology and Eye Care. The company has a robust pipeline of new products that are in some stage of clinical trials. In most cases, trials are underway for multiple indications, including some therapies that have already been approved for 1 or more conditions.

AbbVie is a leader in ESG and sustainability. The company is a member of the Fortune 100 and one of the Fortune 100’s “Best Companies To Work For”. It is a Top 50 Company regarding diversification and a member of the Dow Jones Sustainability World Index and the S&P ESG Index. Among its many positions is sustainable operations so it can deliver life-changing therapies to those who need them most.

ABBV Stock Price History

ABBV Stock News Headlines

Nvidia's AI Tech Part of Novo Nordisk's New Supercomputer (ABBV)
Novo Nordisk and Nvidia have teamed up to develop supercomputers, aiming to accelerate drug discovery development using advanced AI technologies.
Top Project Outperforms BTC in 2023…
According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.
Top 5 Bear Market Stocks to Watch in 2024
Want income-producing assets and stable stocks? Look for stocks with stable cash flow in rock-solid industries for the best stocks to buy in a bear market.
AbbVie (NYSE:ABBV) Given New $195.00 Price Target at Barclays
Top Project Outperforms BTC in 2023…
According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.
AbbVie (NYSE:ABBV) Trading 0.1% Higher on Analyst Upgrade
AbbVie: An Undervalued Giant
AbbVie (NYSE:ABBV) Trading Up 0.1% Following Analyst Upgrade
AbbVie (NYSE:ABBV) Shares Up 0.2% Following Analyst Upgrade
AbbVie (NYSE:ABBV) Stock Price Up 0.2% After Analyst Upgrade
See More Headlines
Receive ABBV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AbbVie and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Ex-Dividend for 2/15 Dividend
1/12/2024
Last Earnings
2/02/2024
Dividend Payable
2/15/2024
Today
3/28/2024
Ex-Dividend for 5/15 Dividend
4/12/2024
Next Earnings (Estimated)
4/25/2024
Dividend Payable
5/15/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
CUSIP
00287Y10
Employees
50,000
Year Founded
2013

Price Target and Rating

Average Stock Price Target
$177.43
High Stock Price Target
$196.00
Low Stock Price Target
$150.00
Potential Upside/Downside
-2.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.71
Research Coverage
14 Analysts

Profitability

Net Income
$4.86 billion
Pretax Margin
11.51%

Debt

Sales & Book Value

Annual Sales
$54.32 billion
Cash Flow
$16.07 per share
Book Value
$5.78 per share

Miscellaneous

Outstanding Shares
1,770,650,000
Free Float
1,766,220,000
Market Cap
$322.44 billion
Optionable
Optionable
Beta
0.58

Social Links

7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Should I Buy AbbVie Stock? ABBV Pros and Cons Explained

These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of AbbVie was last updated on Tuesday, March 26, 2024 at 12:14 AM.

Pros

Here are some ways that investors could benefit from investing in AbbVie:

  • AbbVie offers a diverse range of pharmaceutical products, including Humira, Skyrizi, and Rinvoq, which have shown effectiveness in treating various diseases such as autoimmune conditions, psoriasis, and arthritis.
  • Recent collaborations with leading biotech companies like Calico Life Sciences LLC and REGENXBIO Inc. indicate AbbVie's commitment to innovation and expanding its product pipeline.
  • Strong financial performance with consistent revenue growth and profitability, providing stability and potential returns for investors.
  • AbbVie's focus on research and development ensures a continuous stream of new treatments, enhancing its competitive position in the pharmaceutical industry.
  • Current stock price of AbbVie reflects a favorable valuation compared to its peers, presenting a potential opportunity for value investors.

Cons

Investors should be bearish about investing in AbbVie for these reasons:

  • AbbVie faces risks associated with patent expirations of key drugs, which could lead to revenue declines as generic competition enters the market.
  • The pharmaceutical industry is highly regulated, and changes in healthcare policies or regulations could impact AbbVie's operations and financial performance.
  • Dependency on a few blockbuster drugs like Humira for a significant portion of revenue poses a concentration risk if sales of these products decline unexpectedly.
  • Ongoing legal challenges and patent disputes may result in increased legal costs and uncertainties, affecting AbbVie's bottom line.
  • Market competition and the need for continuous innovation in drug development require significant investments, which could impact AbbVie's profitability and cash flow.

ABBV Stock Analysis - Frequently Asked Questions

Should I buy or sell AbbVie stock right now?

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AbbVie in the last year. There are currently 4 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" ABBV shares.
View ABBV analyst ratings
or view top-rated stocks.

What is AbbVie's stock price target for 2024?

14 brokerages have issued 1 year target prices for AbbVie's stock. Their ABBV share price targets range from $150.00 to $196.00. On average, they expect the company's stock price to reach $177.43 in the next year. This suggests that the stock has a possible downside of 2.5%.
View analysts price targets for ABBV
or view top-rated stocks among Wall Street analysts.

How have ABBV shares performed in 2024?

AbbVie's stock was trading at $154.97 at the beginning of the year. Since then, ABBV shares have increased by 17.4% and is now trading at $181.97.
View the best growth stocks for 2024 here
.

Are investors shorting AbbVie?

AbbVie saw a increase in short interest in the month of February. As of February 15th, there was short interest totaling 14,750,000 shares, an increase of 7.5% from the January 31st total of 13,720,000 shares. Based on an average daily volume of 5,320,000 shares, the short-interest ratio is presently 2.8 days. Currently, 0.8% of the shares of the company are short sold.
View AbbVie's Short Interest
.

When is AbbVie's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 25th 2024.
View our ABBV earnings forecast
.

How were AbbVie's earnings last quarter?

AbbVie Inc. (NYSE:ABBV) posted its quarterly earnings results on Friday, February, 2nd. The company reported $2.79 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.76 by $0.03. The company had revenue of $14.30 billion for the quarter, compared to the consensus estimate of $14.02 billion. AbbVie had a trailing twelve-month return on equity of 162.28% and a net margin of 8.95%. The business's revenue for the quarter was down 5.4% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $3.60 earnings per share.
Read the conference call transcript
.

How often does AbbVie pay dividends? What is the dividend yield for AbbVie?

AbbVie declared a quarterly dividend on Thursday, February 15th. Stockholders of record on Monday, April 15th will be paid a dividend of $1.55 per share on Wednesday, May 15th. This represents a $6.20 dividend on an annualized basis and a yield of 3.41%. The ex-dividend date of this dividend is Friday, April 12th.
Read our dividend analysis for ABBV
.

Is AbbVie a good dividend stock?

AbbVie (NYSE:ABBV) pays an annual dividend of $6.20 per share and currently has a dividend yield of 3.46%. The company has been increasing its dividend for 52 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio is 227.11%. Payout ratios above 75% are not desirable because they may not be sustainable. Based on earnings estimates, ABBV will have a dividend payout ratio of 50.82% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for ABBV.

What guidance has AbbVie issued on next quarter's earnings?

AbbVie updated its FY24 earnings guidance on Monday, February, 12th. The company provided earnings per share guidance of $11.05-$11.25 for the period, compared to the consensus earnings per share estimate of $11.21.

What is Richard A. Gonzalez's approval rating as AbbVie's CEO?

580 employees have rated AbbVie Chief Executive Officer Richard A. Gonzalez on Glassdoor.com. Richard A. Gonzalez has an approval rating of 88% among the company's employees.

What other stocks do shareholders of AbbVie own?
Who are AbbVie's major shareholders?

AbbVie's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (9.08%), Vanguard Group Inc. (8.91%), Capital International Investors (2.50%), Capital Research Global Investors (1.68%), Charles Schwab Investment Management Inc. (1.36%) and Northern Trust Corp (1.16%). Insiders that own company stock include Azita Saleki-Gerhardt, Brian L Durkin, Carrie C Strom, Carrie C Strom, Elaine K Sorg, Henry O Gosebruch, Jeffrey Ryan Stewart, Kevin K Buckbee, Laura J Schumacher, Michael Severino, Nicholas Donoghoe, Perry C Siatis, Richard A Gonzalez, Robert A Michael, Roxanne S Austin, Scott T Reents and Timothy J Richmond.
View institutional ownership trends
.

How do I buy shares of AbbVie?

Shares of ABBV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does AbbVie have any subsidiaries?
The following companies are subsidiares of AbbVie: AbbVie (Gibraltar) Holdings Limited, AbbVie (Gibraltar) Holdings Limited Luxembourg S.C.S., AbbVie (Gibraltar) Limited, AbbVie (Pty) Ltd., AbbVie A/S, AbbVie AB, AbbVie AG, AbbVie AS, AbbVie Australasia Holdings Limited, AbbVie B.V., AbbVie Bahamas Ltd., AbbVie Biofarmacevtska družba d.o.o., AbbVie Biopharmaceuticals GmbH, AbbVie Biopharmaceuticals LLC, AbbVie Biopharmaceuticals Ltd., AbbVie Bioresearch Center Inc., AbbVie Biotech Ventures Inc., AbbVie Biotechnology GmbH, AbbVie Biotechnology Ltd, AbbVie Biotherapeutics Inc., AbbVie Biotherapeutics Limited, AbbVie Central Finance B.V., AbbVie Corp, AbbVie Corporation, AbbVie Deutschland GmbH & Co. KG, AbbVie EOOD, AbbVie Endocrine Inc., AbbVie Endocrinology Inc., AbbVie Farmacéuticos S.A. de C.V., AbbVie Farmacêutica Ltda., AbbVie Finance B.V., AbbVie Finance Corporation, AbbVie Finance LLC, AbbVie GK, AbbVie GmbH, AbbVie Holdings Corporation, AbbVie Holdings Inc., AbbVie Holdings KK, AbbVie Holdings SAS, AbbVie Holdings Unlimited, AbbVie Holdings s.r.o., AbbVie International S.à r.l., AbbVie Investments Limited, AbbVie Investments S.à r.l., AbbVie Ireland Holdings Limited, AbbVie Ireland NL B.V., AbbVie Ireland Unlimited Company, AbbVie Japan Holdings B.V., AbbVie Kft., AbbVie Komplementär GmbH, AbbVie L.L.C., AbbVie L.da, AbbVie Limited, AbbVie Limited Liability Company, AbbVie Logistics B.V., AbbVie Ltd, AbbVie Ltd., AbbVie Manufacturing Management Limited, AbbVie Nederland Holdings B.V., AbbVie Operations Singapore Pte. Ltd., AbbVie Overseas S.à r.l., AbbVie Oy, AbbVie Participações Ltda., AbbVie Pharmaceutical Trading (Shanghai) Co. Ltd., AbbVie Pharmaceuticals B.V., AbbVie Pharmaceuticals GmbH, AbbVie Pharmaceuticals LLC, AbbVie Pharmaceuticals SCA., AbbVie Pharmaceuticals Societe Anonyme, AbbVie Polska Sp. z o.o., AbbVie Productos Farmacéuticos Limitada, AbbVie Products LLC, AbbVie Promoção L.da, AbbVie Pte. Ltd., AbbVie Pty Ltd, AbbVie Purchasing LLC, AbbVie Real Estate Management GmbH, AbbVie Research B.V., AbbVie Resources Inc., AbbVie Resources International Inc., AbbVie Respiratory LLC, AbbVie S. de R.L., AbbVie S.A., AbbVie S.A., AbbVie S.A.S., AbbVie S.R.L., AbbVie S.r.l., AbbVie S.à r.l., AbbVie SA, AbbVie SAS, AbbVie SIA, AbbVie Sarl, AbbVie Sdn. Bhd., AbbVie Sp. z o.o., AbbVie Spain S.L., AbbVie Stemcentrx LLC, AbbVie Trading S.R.L., AbbVie Trustee Company Limited, AbbVie Tıbbi İlaçlar Sanayi ve Ticaret Limited Şirketi, AbbVie UAB, AbbVie UK Biopharmaceuticals Ltd, AbbVie UK Holdco Limited, AbbVie UK Ltd, AbbVie US Holdings LLC, AbbVie US LLC, AbbVie Venezuela B.V., AbbVie Venezuela Holdings B.V., AbbVie Ventures LLC, AbbVie d.o.o., AbbVie s.r.o., Aeropharm Technology LLC, Allergan, BioDisplay Technologies Inc., Fournier Laboratories Ireland Ltd., Fremont Holding L.L.C., Fundación AbbVie, IEP Pharmaceutical Devices LLC, ImmuVen, KOS Pharmaceuticals Inc., Knoll LLC, Knoll Pharmaceutical Company, Life Properties Inc., Mavupharma, Organics L.L.C., Pharmacyclics (Europe) Limited, Pharmacyclics (Shanghai) Management Consulting Services Limited, Pharmacyclics Cayman Ltd., Pharmacyclics Inc, Pharmacyclics LLC, Pharmacyclics Switzerland GmbH, Rowell Laboratories Inc., S.C. AbbVie S.R.L., Sapphire Merger Sub Inc., Stem CentRx, Stemcentrx Cayman Ltd., Suffolk Merger Sub Inc., and Unimed Pharmaceuticals LLC.
Read More
This page (NYSE:ABBV) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners